Risk of thromboembolic complications during hormone therapy
https://doi.org/10.30629/0023-2149-2022-100-1-11-17
Abstract
The review presents modern data of the effect of hormonal contraceptives and hormone replacement therapy drugs on the risk of thromboembolic complications. The effect of components of the drugs and their dosages on the hemostasis system is presented, the use of hormonal therapy in women with extragenital diseases is discussed, the ways of reducing the thrombogenic risk of hormones with their mandatory use are debated.
About the Authors
A. P. Mel’nikov
Moscow Regional Research Institute of Obstetrics and Gynecology
Russian Federation
Russian Federation
Mel’nikov Andrey P.
101000, Moscow
V. A. Fedorenko
Moscow Regional Research Institute of Obstetrics and Gynecology
Russian Federation
Russian Federation
Fedorenko Victoria A.
101000, Moscow
References
1. Nicholson M., Chan N., Bhagirath V., Ginsberg J. Prevention of venous thromboembolism in 2020 and beyond. Clin. Med. 2020;9(8):2467. DOI: 10.3390/jcm9082467
2. Lidegaard Ø., Nielsen L.H., Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 BMJ. 2012;344:e2990. DOI: 10.1136/bmj.e2990
3. Keenan L., Kerr T., Duane M., Van Gundy K. Systematic Review of Hormonal Contraception and Risk of Venous Thrombosis. Linacre Q. 2018;85(4):470–477. DOI: 10.1177/0024363918816683
4. Abou-Ismail M.Y., Sridhar D.C., Nayak L. Estrogen and Thrombosis: a Bench to Bedside Review. Throm.b Res. 2020;192:40–51. DOI: 10.1016/j.thromres.2020.05.008
5. Manzoli L. Oral Contraceptives and Venous Thromboembolism a Systematic Review and Metaanalysis. Drug. Saf. 2012;35(3):191– 205. DOI: 10.2165/11598050-000000000-00000
6. Römer T. Medical eligibility for contraception in women at increased risk. Dtsch Arztebl. Int. 2019;116(45):764–774. DOI: 10.3238/arztebl.2019.0764
7. Regidor P.A. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. 2018;9(77):34628–34638. DOI: 10.18632/oncotarget.26015
8. Shufelt C.L., Pacheco C., Tweet M.S., Miller V.M. Sex-specific physiology and cardiovascular disease. Adv. Exp. Med. Biol. 2018;1065:433–454. DOI: 10.1007/978-3-319-77932-4_27
9. Per Morten Sandset Mechanisms of hormonal therapy related thrombosis. Thromb. Res. 2013;131(1):4–7. DOI: 10.1016/S0049-3848(13)70009-4
10. Gialeraki A., Valsami S., Pittaras T., Panayiotakopoulos G., Politou M. Oral contraceptives and HRT risk of thrombosis. Clin. Appl. Thromb. Hemost. 2016. DOI: 10.1177/1076029616683802
11. van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J., Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009;339:b2921. DOI: 10.1136/bmj.b2921
12. Khialani D., Rosendaal F., van Hylckama Vlieg A. Hormonal Contraceptives and the Risk of Venous Thrombosis. Semin. Throm.. Hemos. 2020;46(8):865–871. DOI: 10.1055/s-0040-1715793
13. Schindler A.E. Differential effects of progestins on hemostasis. Maturitas. 2003;46(1):31–7. DOI: 10.1016/j.maturitas.2003.09.016
14. Eyster K.M. The estrogen receptors: an overview from different perspectives, in Estrogen Receptors. Methods Mol. Biol. 2016;1366:1–10. DOI: 10.1007/978-1-4939-3127-9_1
15. Tepper N.K., Dragoman M.V., Gaffi eld M.E., Curti K.M. Non-oral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception. 2017;95(2):130–139. DOI: 10.1016/j.contraception.2016.10.005
16. Mantha S., Karp R., Zwicker J.I. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ. 2012;345:e4944. DOI: 10.1136/bmj.e4944
17. Wiegratz I., Bassol S., Merz M. Effect of a low-dose contraceptive patch on effi cacy, bleeding pattern, and safety. Reprod. Sci. 2014;21(12):1518–25. DOI: 10.1177/1933719114532840
18. Rafiei F., Tabesh H., Mottaghy K. Development of Hormonal Intravaginal Rings: Technology and Challenges. Geburtshilfe Frauenheilkd. 2021;81(7):789–806. DOI: 10.1055/a-1369-9395
19. Brull E.P., Fernandes A., Monteiro I., Bahamondes L., Juliato C.R.T. Safety and bleeding patterns of the levonorgestrel 52-mg intrauterine system among women with thrombosis or coagulopathy. Int. J. Gynaecol. Obstet. 2020;151(3):355–361 DOI: 10.1002/ijgo.13378
20. Gray B., Floyd S., James A.H. Contraceptive Management for Women Who Are at High Risk of Thrombosis. Clin. Obstet. Gynecol. 2018;61(2):243–249 DOI: 10.1097/GRF.0000000000000356
21. Mari D., Ogliari G., Castaldi D., Vitale G., Bollini E.M., Lio D. Hemostasis and ageing. Immun. Ageing. 2008;5:12. DOI: 10.1186/1742-4933-5-12
22. Połać I., Borowiecka M., Wilamowska A., Nowak P. Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration. Gynecol. Endocrinol. 2013;29(2):165-8. DOI: 10.3109/09513590.2012.730567
23. Barmas-Alamdari D., Sodhi G.S., Spitze A.R. Extensive cerebral venous sinus thrombosis due to medroxyprogestero ne acetate. Neuroophthalmology. 2020;45(1):52–55. DOI: 10.1080/01658107.2020.1797823
24. Hugon-Rodin J., Alhenc-Gelas M., Hemker H.C., Brailly-Tabard S., Guiochon-Mantel A., PluBureau G., Scarabin P.Y. Sex hormone-binding globulin and thrombin generation in women using hormonal contraception. Biomarkers. 2017;22(1):81–85. DOI: 10.1080/1354750X.2016.1204010
25. Arathimos R., Millard L.A.C., Bell J.A., Relton C.L., Suderman M. Impact of sex hormone-binding globulin on the human phenome. Hum. Mol. Genet. 2020;29(11):1824–1832. DOI: 10.1093/hmg/ddz269
26. Simons P.I.H.G., Valkenburg O., Stehouwer C.D.A., Brouwers M.C.G.J. Sex hormone-binding globulin: biomarker and hepatokine? Trends Endocrinol Metab. 2021;32(8):544–553. DOI: 10.1016/j.tem.2021.05.002
27. Kemmeren J.M. et al., Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V (Leiden) mutation: a randomized trial. Blood. 2004;103(3):927–33. DOI: 10.1182/blood-2003-04-1285
28. Ali H.O., Stavik B., Dørum E., Iversen N., Sandset P.M., Skretting G. Oestrogen induced downregulation of TFPI expression is mediated by ERα. Thromb. Res. 2014;134(1):138–43. DOI: 10.1016/j.thromres.2014.04.004
29. Kline J.A., Richardson D.M., Than M.P., Penaloza A., Roy P.M. Systematic review and meta-analysis of pregnant patients investigated for suspected pulmonary embolism in the emergency department. Acad. Emerg. Med. 2014;21(9):949–59. DOI: 10.1111/acem.12471
Review
For citations:
Mel’nikov A.P., Fedorenko V.A. Risk of thromboembolic complications during hormone therapy. Clinical Medicine (Russian Journal). 2022;100(1):11-17. (In Russ.) https://doi.org/10.30629/0023-2149-2022-100-1-11-17
Views:
502
Email this article 